Multiparameter Evaluation of the Platelet-Inhibitory Effects of Tyrosine Kinase Inhibitors Used for Cancer Treatment

B.M.E. Tullemans, A. Veninga, D.I. Fernandez, M.J.B. Aarts, J.A. Eble, P.E.J. van der Meijden, J.W.M. Heemskerk, M.J.E. Kuijpers*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Current antiplatelet drugs for the treatment of arterial thrombosis often coincide with increased bleeding risk. Several tyrosine kinase inhibitors (TKIs) for cancer treatment inhibit platelet function, with minor reported bleeding symptoms. The aim of this study was to compare the antiplatelet properties of eight TKIs to explore their possible repurposing as antiplatelet drugs. Samples of whole blood, platelet-rich plasma (PRP), or isolated platelets from healthy donors were treated with TKI or the vehicle. Measurements of platelet aggregation, activation, intracellular calcium mobilization, and whole-blood thrombus formation under flow were performed. Dasatinib and sunitinib dose-dependently reduced collagen-induced aggregation in PRP and washed platelets; pazopanib, cabozantinib, and vatalanib inhibited this response in washed platelets only; and fostamatinib, axitinib, and lapatinib showed no/limited effects. Fostamatinib reduced thrombus formation by approximately 50% on collagen and other substrates. Pazopanib, sunitinib, dasatinib, axitinib, and vatalanib mildly reduced thrombus formation on collagen by 10-50%. Intracellular calcium responses in isolated platelets were inhibited by dasatinib (> 90%), fostamatinib (57%), sunitinib (77%), and pazopanib (82%). Upon glycoprotein-VI receptor stimulation, fostamatinib, cabozantinib, and vatalanib decreased highly activated platelet populations by approximately 15%, while increasing resting populations by 39%. In conclusion, the TKIs with the highest affinities for platelet-expressed molecular targets most strongly inhibited platelet functions. Dasatinib, fostamatinib, sunitinib, and pazopanib interfered in early collagen receptor-induced molecular-signaling compared with cabozantinib and vatalanib. Fostamatinib, sunitinib, pazopanib, and vatalanib may be promising for future evaluation as antiplatelet drugs.</p>
Original languageEnglish
Article number11199
Number of pages18
JournalInternational Journal of Molecular Sciences
Volume22
Issue number20
DOIs
Publication statusPublished - 1 Oct 2021

Keywords

  • platelet activation
  • aggregation
  • bleeding
  • thrombus formation
  • tyrosine kinase inhibitors
  • antiplatelet treatment
  • IN-VIVO DEPLETION
  • GLYCOPROTEIN-VI
  • THROMBUS FORMATION
  • RECEPTOR CLEC-2
  • ACTIVATION
  • GPVI
  • EXPRESSION
  • DEFICIENT
  • INTEGRIN
  • BLOOD

Cite this